Monday 16th March 2020
|Text too small?|
Blis Technologies (NZX: BLT ) announced today that it has upgraded its revenue and earnings guidance for the financial year ended 31 March 2020. Guidance provided in February was for revenue in excess of $9.4m and EBITDA in excess of $1.0m. The company expects full year revenue of around $10.0m and EBITDA of between $1.5m to $1.7m, subject to completion of existing orders and audit.
Sharp increases in sales of our BLISTM finished goods are complementing a strong year of sales of our branded ingredients into international markets. Additionally, a portion of scheduled project expenditure has been deferred to next financial year due to delays caused by the impacts of COVID-19.
Brian Watson, CEO said, “Sales of our BLIS probiotic brands through pharmacies and online channels in February and March were better than expected. This increase is across the Blis range but is particularly evident for our products with an immune boosting proposition. BLIS TravelProtectTM, UltraBLISTM, DailyDefenceTM and ThroatGuard PROTM have all seen a lift in sales over this period.”
“We have noted media reports of immunity products seeing a lift in demand globally and it appears some of our current increased sales are related to COVID-19 concerns. We believe consumers are looking for products that may help support natural immunity.” “To date our supply chain, from ingredient supply through to manufacture of finished product has been able to meet the lift in demand and we have significantly increased our production to meet anticipated forward orders. We continue to monitor our supply chain for any future constraints.”
Results for the 12 months to 31 March 2020 are expected to be announced in late May.
No comments yet
Proposal for VHP ASX foreign exempt listing not proceeding
The Reserve bank’s temporary ban affects more than $1b of securities
Yesterday Kathmandu confirmed it was raising $207m in order to cope and help it survive the turbulent Covid -19 pandemic
NZ banks not allowed to pay dividends until recovery, RBNZ announces
RBNZ changes affecting ANB Capital Notes
Trading update and completion of big chill acquisition
Turners Maintains FY20 Profit Guidance: Focus on C-19 Plan
Urgent Demand for Medical Equipment Is Making Air Cargo Fees ‘Absolutely Crazy’
J&J and Abbott announce potential coronavirus vaccine and rapid test